Propanc Biopharma Inc (PPCB) FinancialsPPCBPropanc Biopharma Inc

Evaluating the bottom line, Propanc Biopharma Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -169.86%, provide a clear picture of how effectively PPCB converts its operational activities into shareholder value.

In the context of the broader market, PPCB competes directly with industry leaders such as ENLV and GOVX. With a market capitalization of $1.80M, it holds a significant position in the sector. When comparing efficiency, PPCB's gross margin of N/A stands against ENLV's N/A and GOVX's N/A. Such benchmarking helps identify whether Propanc Biopharma Inc is trading at a premium or discount relative to its financial performance.

PPCB has shown consistently negative net income, with the latest quarterly net income at -$4,573,242. The gross profit has been zero for multiple quarters, indicating a lack of revenue generation.